Recently we have seen additional examples of favorable changes in laboratory tests without the expected reduction in risk for tight glucose control for diabetes, fibrate therapy for diabetics, and niacin therapy for patients with heart disease.
FORBES: AstraZeneca Study is Good News for the Public, Bad News for AstraZeneca